BeiGene further invests in ADCs with solid tumor partner DualityBio, a BioNTech collaborator

Kyle LaHucik

Senior Reporter

BeiGene is expanding its cancer arsenal with an antibody-drug conjugate deal, enlisting the same Shanghai biotech that teamed up with BioNTech in April.

The solid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BeiGene further invests in ADCs with solid tumor partner DualityBio, a BioNTech collaborator

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

China startup injects CRISPR therapy into the brain for the first time

Roivant brings rare disease program closer as Immunovant CEO retires

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

BeiGene fur­ther in­vests in AD­Cs with sol­id tu­mor part­ner Du­al­i­ty­Bio, a BioN­Tech col­lab­o­ra­tor

Senior Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

BeiGene further invests in ADCs with solid tumor partner DualityBio, a BioNTech collaborator